A Study to Evaluate the Efficacy and Tolerability of Everolimus following the First VEGF-targeted Therapy in Patients with Metastatic Renal Cell Carcinoma (mRCC)

Trial Profile

A Study to Evaluate the Efficacy and Tolerability of Everolimus following the First VEGF-targeted Therapy in Patients with Metastatic Renal Cell Carcinoma (mRCC)

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Feb 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CHANGE
  • Most Recent Events

    • 10 Feb 2016 Planned number of patients changed to 360.
    • 09 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top